Liuwei Dihuang Powder Veterinary Grade API is processed into seven distinct downstream delivery forms: tablets, injections, capsules, oral powders, granules, medicated premixes, and oral solutions. The extract powder contains water-soluble iridoid glycosides and polyphenolic tannins, plus hygroscopic polysaccharides from Poria cocos and Dioscorea opposita. These components create three processing conflicts: stickiness during wet granulation, haze formation in aqueous liquids, and segregation in dry blends. Each downstream application therefore requires a separate binder system, drying endpoint, and particle-size specification. In solid dosage lines, pre-drying at 50°C to 60°C under 40% RH is required before blending; the exact endpoint is a loss on drying of 2.5% to 5.0%. Marker standardization against loganin and paeoniflorin is carried out before batch charging because raw extract lots vary with source material and ethanol precipitation ratio.

Is Pregelatinized Starch Binder Level the Main Cause of Extract Tablet Dissolution Loss?

Wet granulation of Liuwei Dihuang extract for animal tablets uses a binder solution of 5% pregelatinized starch or povidone K30 in 50% ethanol. The granulation endpoint is determined by loss on drying and torque rise in the high-shear mixer, not by fixed time, because the extract accepts water unevenly. A batch formulation may combine 250 g extract powder, 180 g microcrystalline cellulose, 40 g croscarmellose sodium, 30 g povidone K30, and 2.5 g magnesium stearate per 1,000 g granule mass. The dry materials are charged into a 150 L high-shear mixer and granulated with the binder at 2.0 m/s impeller speed. Dissolution failure in the finished tablet is more strongly associated with hydrophobic overcompression than with binder level alone. When compression force exceeds 25 kN on a 16-station rotary press, tablet porosity collapses and disintegration time rises above the 30 min limit of CVP 2020 General Chapter 0101. Tablet hardness is maintained at 60 N to 90 N, and friability is held below 1.0% per USP <1216>. Film coating with a 5% aqueous ethylcellulose dispersion is applied only after core moisture falls to 2.0% because residual ethanol in the extract can blister the coat. The terminal product is a 500 mg tablet for swine and cattle oral dosing, with one marker batch release tested by high-performance liquid chromatography at 230 nm for paeoniflorin and 254 nm for loganin.

In production-scale tablet runs, the principal failure mode is edge sticking on the lower punch when granule loss on drying exceeds 5.0%. The condition is corrected by a second drying phase in a fluid-bed dryer at 60°C inlet air and 35% RH until moisture returns to 3.0%. A common incompatibility is the early addition of magnesium stearate above 1.0%, which retards disintegration and slows marker release. The formulation therefore adds magnesium stearate at 0.25% to 0.5% in the final blending step. The batch is released under 21 CFR 211.110 in-process sampling and VICH GL3 stability protocols.

Injectable dosage development with Liuwei Dihuang extract begins with removal of polysaccharides exceeding 10 kDa to 15 kDa and tannins that form insoluble complexes with metal ions in Water for Injection. A 1:10 decoction at 90°C for 2 h is filtered through a 0.45 µm polypropylene depth filter, cooled to 4°C for 12 h, and then precipitated with ethanol at 60% final concentration. The clarified liquid is concentrated under vacuum at 60°C, reconstituted, and passed through a 10 kDa polyethersulfone ultrafiltration cassette. The resulting permeate is adjusted to a product concentration of 10 mg to 20 mg total solids per mL. Sterility assurance is achieved by aseptic filtration through a 0.22 µm PVDF membrane with a bubble point test above 3.2 bar for the water-wetted membrane, followed by filling in an ISO 14644-1:2015 Class 5 zone. Bacterial endotoxin is controlled by the formula K/M, where K is 5 EU/kg/h for the target species; for a 1 mL/kg dose, the calculated limit is 5 EU/mL. Terminal autoclaving at 121°C for 15 min is applicable only if paeoniflorin degradation is validated in VICH GL3 stress studies. The finished injectable is a clear brown liquid for intramuscular or subcutaneous administration, with subvisible particle inspection by light obscuration per USP <788>.

Residual polysaccharide concentration above 0.5 mg/mL tends to precipitate during cold storage and must be rejected if visible particles exceed USP <788> limits. The injection pathway also requires absence of ethanol, full depyrogenation of vials at 250°C for 30 min, and avoidance of amine-based pH adjusters because reducing sugars in the extract can undergo Maillard reactions. Published data for this specific botanical injectable configuration is limited; therefore process validation under 21 CFR 211.110 must include three consecutive process qualification batches.

When Roller-Compacted Granules Enter Capsule Dosators Without Forced Feeding

Capsule filling of Liuwei Dihuang extract is performed with roller-compacted granules rather than direct fill because the milled extract has a Carr Index above 35 and tends to cake in the hopper. The formulation contains 55% dry granulated extract, 25% lactose monohydrate, 10% crospovidone, 5% low-substituted hydroxypropyl cellulose, and 0.5% fumed silica. Roller compaction is operated at a roll pressure of 4 MPa to 6 MPa and ribbon thickness of 1.2 mm to 1.5 mm. The ribbons are milled through a 1.0 mm screen to produce granules with 20% to 30% fines. Without forced feeding, dosator pin carryback causes fill weight drift as the hopper empties; the observed drift can exceed 7.5% after 4 h of continuous operation. A forced-feed auger set to 60 rpm and hopper humidity below 35% RH restores fill weight drift to under 3.0%. Capsule shells of size 1 are filled to 320 mg to 400 mg, and batch release includes USP <905> weight variation and USP <711> dissolution in 900 mL of 0.1 M hydrochloric acid at 37°C. Dissolution below 80% at 60 min is investigated for granule overcompaction and lubricant migration. The terminal product is an oral capsule for companion animals and swine, without enteric coating.

The following compliance matrix summarizes the test designations used across the solid, liquid, and feed-additive pathways.

Oral powders for feed top-dressing use the spray-dried or vacuum-dried extract at 10% to 20% active concentration in a water-soluble carrier. A batch of 1,000 kg may contain 150 kg Liuwei Dihuang extract, 810 kg lactose monohydrate, 30 kg citric acid anhydrous, and 10 kg colloidal silicon dioxide. The active extract is first passed through an 80 mesh sieve to remove crusts formed during storage. The carrier and acid are blended in a 2,000 L ribbon blender at 30 rpm for 10 min before the active extract is added by sequential dilution at 1:5 steps. Blend uniformity is confirmed by 10 sampling points across the discharge gate, with a loganin assay relative standard deviation below 5.0%. This conventional practice requires no further expansion because the operation is a single blending step; the only process conflict is moisture uptake at relative humidity above 60%, which forms lumps in the 0.5 mm sachet fill auger. The finished powder is packed in low-density polyethylene-aluminum foil sachets with a fill tolerance of ±5.0%. The terminal use is metered addition to drinking water or moist feed for pigs and chickens. Where rapid water solubility is required, the extract is replaced with a spray-dried formulation containing 1% poloxamer 188 as wetting agent.

Controlled Porosity in Fluid Bed Granules Through Spray Rate and Dew Point

Granulation for veterinary oral granules requires porous, dust-free agglomerates that disperse in drinking water. The starting powder is a 40% extract, 30% maize starch, 18% dextrin, 10% sucrose, and 2% povidone K30 dry blend. In a top-spray fluid bed with 10 kg working capacity, a binder solution of 5% povidone in 50% ethanol is sprayed at 1.0 mL/min/kg to 1.5 mL/min/kg, with inlet air at 65°C to 70°C, atomization pressure at 1.5 bar to 2.0 bar, and dew point at 8°C to 10°C. When the spray rate exceeds 1.8 mL/min/kg, the extract softens and the bottom screen blinds, causing collapse of the fluidized bed. At spray rate below 0.8 mL/min/kg, granule porosity increases but mechanical strength drops; the resulting granules disintegrate during packaging. The endpoint is a loss on drying of 2.0% to 3.0% and particle size distribution with a D50 between 250 µm and 400 µm. The dried granules are classified through 16 mesh and 40 mesh screens to remove oversized fragments and fines. The terminal product is a 250 mg/g granule for feed top-dressing or direct oral administration, with sachet fill tolerances of ±5.0%. Handling at RH >55% is controlled by immediate sealing because the dextrin phase absorbs water and shifts granule bulk density.

Premix Homogeneity Decay and Carrier-Adsorbate Interface Controls

Liuwei Dihuang powder for medicated feed premix is first diluted with a mineral or lignocellulose carrier before feed-mill distribution. A typical finished premix contains 100 g to 500 g extract per 25 kg bag, with the extract adsorbed onto rice hull flour or calcium carbonate at 1:5 to 1:10 stepwise dilution. In a double-ribbon mixer with 500 kg capacity, a mixing time of 8 min to 12 min at 25 rpm achieves a coefficient of variation below 5.0% for loganin. Homogeneity decay occurs after discharge when vibration from screw conveyors causes the high-density calcium carbonate carrier to settle and the lighter extract-coated particles to rise. The condition is mitigated by using a mixture of 70% rice hull flour and 30% calcium carbonate, with 0.5% vegetable oil added at the final dilution stage to reduce dust and electrostatic segregation. The premix is then incorporated into finished feed at 2% to 5% of total ration. Batch records reference 21 CFR 211.110 in-process sampling and VICH GL3 stability for premix packaged in woven polyethylene gusseted bags with inner film. The terminal product is a feed-mill premix, not a final animal dose; direct feeding of undiluted premix is prohibited by label restriction.

Oral solution manufacture of Liuwei Dihuang extract is based on a 10 mg/mL to 20 mg/mL total solids preparation in purified water, adjusted to pH 4.5 to 5.5 with citric acid. The hot concentrate is prepared at 80°C for 1 h, cooled, and passed through a 0.45 µm polypropylene filter before the addition of preservatives. A common preservative system is 0.08% to 0.15% methylparaben and 0.01% to 0.02% propylparaben dissolved in 5% propylene glycol; sodium benzoate at 0.1% is an alternative when pH remains below 4.5. The solution is compounded in a closed 1,000 L stainless steel tank with a bottom magnetic mixer at 100 rpm; high shear is avoided because foaming accelerates oxidation of paeoniflorin. A nitrogen sparge at 0.5 NL/min before filling reduces dissolved oxygen to below 1.0 mg/L, tracked with a dissolved oxygen probe. The solution is filled into 500 mL high-density polyethylene bottles with a 10% overage of preservative in the bulk tank to offset partitioning into the bottle wall; published data for this specific botanical matrix and container system is limited, so a VICH GL3 bracketing stability study is required. The terminal product is administered via drinking water at 1 mL per 10 kg body weight, with a 24 h water-space restriction before dosing.